[1] |
ARAGHI M, SOERJOMATARAM I, JENKINS M, et al. Global trends in colorectal cancer mortality:projections to the year 2035[J]. Int J Cancer, 2019, 144(12):2992-3000.
DOI
URL
|
[2] |
OGUNWOBI O O, MAHMOOD F, AKINGBOYE A. Biomarkers in colorectal cancer:current research and future prospects[J]. Int J Mol Sci, 2020, 21(15):5311.
DOI
URL
|
[3] |
VEREMEYKO T, YUNG A W Y, ANTHONY D C, et al. Early growth response gene-2 is essential for M1 and M2 macrophage activation and plasticity by modulation of the transcription factor cebpβ[J]. Front Immunol, 2018, 9:2515.
DOI
PMID
|
[4] |
SUN Y, PAVEY H, WILKINSON I, et al. Role of the IL-33/ST2 axis in cardiovascular disease:a systematic review and meta-analysis[J]. PLoS One, 2021, 16(11):e0259026.
DOI
URL
|
[5] |
CHANG C P, HU M H, HSIAO Y P, et al. ST2 signaling in the tumor microenvironment[J]. Adv Exp Med Biol, 2020, 1240:83-93.
|
[6] |
PUSCEDDU I, DIEPLINGER B, MUELLER T. ST2 and the ST2/IL-33 signalling pathway-biochemistry and pathophysiology in animal models and humans[J]. Clin Chim Acta, 2019, 495:493-500.
DOI
PMID
|
[7] |
GRIESENAUER B, PACZESNY S. The ST2/IL-33 axis in immune cells during inflammatory diseases[J]. Front Immunol, 2017, 8:475.
DOI
PMID
|
[8] |
WANG J, HE M, LI H, et al. Soluble ST2 is a sensitive and specific biomarker for fulminant myocarditis[J]. J Am Heart Assoc, 2022, 11(7):e024417.
DOI
URL
|
[9] |
KRITTAYAPHONG R, PUMPRUEG S, SAIRAT P. Soluble ST2 in the prediction of heart failure and death in patients with atrial fibrillation[J]. Clin Cardiol, 2022, 45(4):447-456.
DOI
PMID
|
[10] |
燕亚茹, 谭鹤, 豆书梅, 等. 可溶性ST2在心力衰竭伴肾功能不全患者中的应用价值[J]. 中国心血管杂志, 2018, 23(6):481-485.
|
[11] |
BERGIS D, KASSIS V, RADEKE H H. High plasma sST2 levels in gastric cancer and their association with metastatic disease[J]. Cancer Biomark, 2016, 16(1):117-125.
DOI
PMID
|
[12] |
KIELER M, UNSELD M, WOJTA J, et al. Plasma levels of interleukin-33 and soluble suppression of tumorigenicity 2 in patients with advanced pancreatic ductal adenocarcinoma undergoing systemic chemotherapy[J]. Med Oncol, 2018, 36(1):1.
DOI
PMID
|
[13] |
LU D P, ZHOU X Y, YAO L T, et al. Serum soluble ST2 is associated with ER-positive breast cancer[J]. BMC Cancer, 2014, 14:198.
DOI
URL
|
[14] |
CUI G, YUAN A, LI Z, et al. ST2 and regulatory T cells in the colorectal adenoma/carcinoma microenvironment:implications for diseases progression and prognosis[J]. Sci Rep, 2020, 10(1):5892.
DOI
|
[15] |
LANDSKRON G, DE LA FUENTE LÓPEZ M, DUBOIS-CAMACHO K, et al. Interleukin 33/ST2 axis components are associated to desmoplasia,a metastasis-related factor in colorectal cancer[J]. Front Immunol, 2019, 10:1394.
DOI
URL
|
[16] |
AKIMOTO M, MARUYAMA R, TAKAMARU H, et al. Soluble IL-33 receptor sST2 inhibits colorectal cancer malignant growth by modifying the tumour microenvironment[J]. Nat Commun, 2016, 7:13589.
DOI
PMID
|
[17] |
TOMINAGA S I, OHTA S, TAGO K. Soluble form of the ST2 gene product exhibits growth promoting activity in NIH-3T3 cells[J]. Biochem Biophys Rep, 2015, 5:8-15.
|
[18] |
李东. 恶性胸水中sST2、Fascin含量与癌细胞恶性增殖、侵袭的相关性研究[J]. 海南医学院学报, 2018, 24(3):369-372.
|